Adipokine Retinol Binding Protein 4 and Cardiovascular Diseases

Ji, Yanjing; Song, Jinyou; Su, Tianhong; Gu, Xiaosong

doi:10.3389/fphys.2022.856298

Cited by 12 publications

(11 citation statements)

References 71 publications

(82 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the immunodepletion enabled detection of more lowexpressed proteins (total 830 DEP versus 730 non-DEP), we did not nd improved resolution of differentially detected peptides for the purposes of the current study. RBP4 (retinol binding protein 4) is an adipokine member of the lipocalin protein family, and is the protein carrier for retinol (vitamin A) in blood (21,22). RBP4 has previously been implicated as a biomarker for metabolic syndrome and cardiovascular disease (21)(22)(23).…”

Section: Discussionmentioning

confidence: 99%

Exploratory mass spectrometry of cerebrospinal fluid from persons with autopsy-confirmed LATE-NC

Gal,

Vary,

Gartner

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Common neuropathologies associated with dementia include Alzheimer’s disease neuropathologic change (ADNC) and limbic-predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC). Biofluid proteomics provides a window into the pathobiology of dementia and the information from biofluid tests may help guide clinical management. Methods: Participants were recruited from a longitudinal cohort of older adults at the University of Kentucky AD Research Center. A convenience sample of clinically obtained lumbar puncture cerebrospinal fluid (CSF) samples was analyzed from 29 older adults that had autopsy confirmation of the presence or absence of LATE-NC. Nine of the participants had autopsy-confirmed LATE-NC. Antemortem CSF specimens were analyzed in two separate processes: From one group, aliquots were depleted of highly abundant proteins using affinity spin columns. Tryptic digests of sample proteins were subjected to liquid chromatographic separation and mass spectrometry using an Eksigent Ekspert nanoLC 400 system in line with a Sciex 6600+ mass spectrometer. Protein identification was performed using Protein Pilot (Sciex, ver. 5) software, and relative quantification was performed using the SWATH processing microApp in PeakView and MarkerView software (Sciex), respectively. Following data analyses, additional studies were performed using western blots. Results: A total of 830 proteins were identified in the samples depleted of abundant proteins, and 730 proteins were identified in the non-depleted samples. Whereas some dementia-related proteins were detected (Aβ peptide and α-synuclein protein), others were not (TDP-43, TMEM106B, and tau proteins). When the Bonferroni correction was applied to correct for multiple comparisons, only 4 proteins showed differential expression (LATE-NC vs non-LATE-NC) in the nondepleted samples (RBP4, MIF, IGHG3 and ITM2B), whereas none showed statistically different changes in the depleted samples. Post-hoc western blots confirmed that RBP4 expression was higher in the LATE-NC cases at the group level, but there was overlap between the levels of RBP4 in LATE-NC and non-LATE-NC cases. Conclusions: An exploratory assessment of CSF proteomes of autopsy-confirmed LATE-NC and non-LATE-NC cases from a community-based cohort failed to demonstrate a clear-cut proteomic fingerprint that distinguished the two groups. There was intriguing increase in RBP4 protein levels in CSF from LATE-NC cases. This may provide clues about pathogenetic mechanisms in LATE-NC.

show abstract

Section: Discussionmentioning

confidence: 99%

Exploratory mass spectrometry of cerebrospinal fluid from persons with autopsy-confirmed LATE-NC

Gal,

Vary,

Gartner

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Besides the adipokines and cytokines roles in the induction of insulin resistance, it has been found that elevated level of RBP4 may linked to obesity, and other risk factor, such as cardiovascular disease, hypertension, and hyperlipidemia [ 25 , 26 ]. Higher serum concentration of RBP was shown correlated with higher level of glucose, triglycerides, and cholesterol in human [ 27 , 28 ].…”

Section: Vitamin Amentioning

confidence: 99%

Vitamin A: A Key Inhibitor of Adipocyte Differentiation

Malibary

2023

PPAR Research

View full text Add to dashboard Cite

Inhibiting adipocyte differentiation, the conversion of preadipocytes to mature functional adipocytes, might represent a new approach to treating obesity and related metabolic disorders. Peroxisome proliferator-activated receptor γ and CCAAT-enhancer-binding protein α are two master coregulators controlling adipogenesis both in culture and in vivo. Many recent studies have confirmed the relationship between retinoic acid (RA) and the conversion of embryonic stem cells into adipocytes; however, these studies have shown that RA potently blocks the differentiation of preadipocytes into mature adipocytes. Nevertheless, the functional role of RA in early tissue development and stem cell differentiation, including in adipose tissue, remains unclear. This study highlights transcription factors that block adipocyte differentiation and maintain preadipocyte status, focusing on those controlled by RA. However, some of these novel adipogenesis inhibitors have not been validated in vivo, and their mechanisms of action require further clarification.

show abstract

“…Cardiovascular disease (CVD) has become a leading cause of morbidity and mortality among chronic diseases worldwide. [169][170][171][172][173] Atherosclerosis (AS) is considered as one of the primary causes of CVD. [174][175][176] AS usually leads to myocardial ischemia or cerebral ischemia.…”

Section: Biomarker-responsive Nanotheranostics For Cardiovascular Dis...mentioning

confidence: 99%

Biomarker‐Responsive Nanosystems for Chronic Disease Theranostics

Wang

et al. 2022

Adv Funct Materials

View full text Add to dashboard Cite

Chronic diseases claim millions of lives every year, and it is of great significance to explore and develop advanced drugs to improve the cure rate of chronic diseases. Nanotheranostics are innovative strategies that enable the integration of diagnostic and therapeutic properties into a single nanosystem. Despite great success in nanotheranostics, their applications of nanotheranostics in nanomedicine are still in their infancy. This is because each disease has its corresponding characteristic pathological microenvironment, which motivates the development of endogenous biomarker-responsive nanosystems to meet the requirements of diagnosis and treatment. Herein, recent progress is presented in biomarker-responsive nanosystems and their biomedical applications. First, biomarker-responsive nanosystems are classified into eight subsections according to the type of chronic diseases, including tumors, cardiovascular diseases, neurological diseases, Wilson's diseases, chronic liver diseases, chronic kidney diseases, diabetes mellitus, and rheumatoid arthritis. In the following, a variety of intriguing applications of biomarkers-responsive nanosystems are briefly elaborated, such as biosensing, diagnosis, therapy, combined theranostics, and early evaluation of therapy effect, etc. Finally, the challenges and future directions from research to clinical translation of these responsive nanosystems are also presented.

show abstract

Adipokine Retinol Binding Protein 4 and Cardiovascular Diseases

Cited by 12 publications

References 71 publications

Exploratory mass spectrometry of cerebrospinal fluid from persons with autopsy-confirmed LATE-NC

Exploratory mass spectrometry of cerebrospinal fluid from persons with autopsy-confirmed LATE-NC

Vitamin A: A Key Inhibitor of Adipocyte Differentiation

Biomarker‐Responsive Nanosystems for Chronic Disease Theranostics

Contact Info

Product

Resources

About